Briefing
Mosunetuzumab consolidation for older patients with DLBCL and detectable ctDNA after pola-R-mini-CHP
Phase 2 trial in which people with a radiographic complete response but detectable ctDNA receive mosunetuzumab, and those with undetectable ctDNA are observed. The registry primary outcome is the ctDNA clearance rate. ClinicalTrials.gov lists the study as recruiting.
- Design: Phase 2 · Recruiting